Preliminary trials
The mucoadhesive propranolol hydrochloride microspheres prepared from Carbopol-934P and ethyl cellulose were made using the emulsion-solvent evaporation technique. Carbopol-934P chosen for the preparation of mucoadhesive microspheres, owing to its good mucoadhesive properties. Ethyl cellulose was used as a carrier polymer. Different concentrations of span 80, from 1-3% v/v, were used as the emulsifying agent. Span 80 was found to have a significant influence on the percentage of mucoadhesion observed (i.e. percentage of microspheres adhered and remained on the gastric mucous layer), particles size and drug entrapment efficiency. Results showed that increase in the concentration of span 80, increased the particle size of microspheres, as well as the percentage of mucoadhesion. However, the drug entrapment efficiency was decreased. At a 1% v/v span80 concentration, percentage of mucoadhesion, particle size and drug entrapment efficiency of microspheres were 65%, 82 μm and 64 % respectively. However, formation of irregularly shaped microspheres was observed. On the other hand, at 3% v/v span 80 concentration, the percentage of mucoadhesion, particles size and drug entrapment efficiency of microspheres were 80%, 208 μm and 39 % respectively. The shapes of microspheres were found to be spherical, particles were coalesced. However, a 2 % v/v of concentration of span 80 was used for further studies.
One of the important factors related to microspheres, as reported by Lee
et al (
27), is the viscosity of the polymer solution. Polymer concentrations of 0.5%, 1%, and 2% w/v were selected for preliminary trials. Flake formation was observed when ethyl cellulose and Carbopol-934P concentration was used at a level of 0.5% w/v, whereas maximum sphericity was observed at the 1% w/v level. Non-spherical microspheres were formed, when 2% w/v using polymer concentrations. Therefore, a 1% w/v concentration of ethyl cellulose and Carbopol-934P, each in ethanol, was found to be the optimum concentration for the polymer solution. A 1:1 mixture of heavy and light liquid paraffin was found to be suitable as the dispersion medium.
Preliminary trial batches were prepared, in order to investigate the effect of stirring time and speed on the percentage of mucoadhesion, drug entrapment efficiency, and characteristics of the resulting microspheres. An increase in the stirring time 1 h to 3 h, showed an increase in the percentage of mucoadhesion, but a decrease in drug entrapment efficiency and particles size of microspheres. Thus, a stirring time 3h was selected for further studies. Since, the stirring speed had a significant effect on the percentage of mucoadhesion, drug entrapment efficiency and particles size of microspheres, it was selected as an important factor for further studies.
On the basis of the preliminary trials, a 3
2 full factorial design was employed to study the effect of independent variables (i.e. drug-to-polymer-to-polymer ratio [
X1] and the stirring speed [
X2]) on dependent variables, which were the percentage of mucoadhesion, drug entrapment efficiency, particle size and t
80. The results depicted in
Table 1 clearly indicate that all the dependent variables are strongly dependent on the selected independent variables, as they show a wide variation among the nine batches (J
1-J
9). The fitted equations (full models), relating the responses (i.e. percentage of mucoadhesion, drug entrapment efficiency, particle size and t
80) to the transformed factor are shown in
Table 3. The polynomial equations can be used to draw conclusions after considering the magnitude of coefficient and the mathematical sign it carries (i.e. positive or negative). The high values of correlation coefficient (
Table 3) for the dependent variables indicate a good fit. The equations may be used to obtain estimates of the response, since a small error of variance was noticed in the replicates.
| Coefficient | b0 | b1 | b2 | b11 | b22 | b12 | R2 |
|---|
| % Mucoadhesion | 77.42 | 14.47 | -8.19 | -2.81 | -9.60 | -0.50 | 0.9809 |
| Drug entrapment efficiency | 48.14 | 7.71 | -3.28 | -4.57 | -16.71 | 0.28 | 0.9165 |
| Particle size | 103.77 | 7.30 | -6.60 | -1.10 | -1.01 | -1.25 | 0.9955 |
| t80 | 533.41 | -167.50 | 43.88 | -46.19 | 3.18 | -23.49 | 0.9997 |
Factorial equation for the percentage of mucoadhesion
The
in-vitro mucoadhesiveness test represented the percentage of mucoadhesive microspheres remaining on the stomach mucosa (
Table 1). The mucoadhesive microspheres of all the of the factorial design batches were spherical (
Figure 1, batch J
4) and free-flowing.
The linear model generated for the percentage of mucoadhesion was found to be significant, with an F-value of 20.64 (p < 0.0001) and R2 value of 0.9809:
% mucoadhesion = 77.42+ 14.47X1 – 8.19X2 -2.81X1X2 -9.6 X22 (5)
The counter plot (
Figure 5a) shows that the in-vitro wash-off test carried out for determining the percentage of mucoadhesion of microspheres, increased from 42 to 58 and 74 to 92, at lower and higher levels of drug-to-polymer-to-polymer ratio, respectively, as the stirring speed decreased. Results obtained, indicated that the effect of
X1 (drug-to-polymer-to-polymer) is more significant than
X2 (stirring speed). Moreover, stirring speed had a negative effect on the percentage of mucoadhesion (i.e. as the stirring speed increased, the percentage of mucoadhesion decreased). This finding may be attributed to a change in particle size, which can consequently affect mucoadhesion. As the drug-to-polymer-to-polymer ratio increases; the percentage of mucoadhesion also increases; since the greater amount of polymer results in a higher amount of free –COOH (carboxyl) groups (
17), which are responsible for binding to the sialic acid groups within the mucus network. Hence, it results in an increase in the mucoadhesive properties of microspheres.
In-vitro mucoadhesive tests showed that propranolol hydrochloride mucoadhesive microspheres adhered more strongly to the gastric mucosa and could be retained in the gastrointestinal tract for an extended period of time (
Figures 2 and
3).
Figure 3 also showed that even after 8 h some of the microspheres were remained on the gastric mucous layer.
Factorial equation for particle size
The linear model generated for particle size of microspheres was found to be significant, with an F-value of 88.76 (p < 0.0001) and R2 value of 0. 9955:
Particle size = 103.77 + 7.3X1 – 6.6X2 -1.0X1X2 -1.0 X22 (6)
The counter plot (
Figure 5b) showed that the particle size of microspheres increased from 88 to 100 μm and 102 to 115 μm, at lower and higher levels of drug-to-polymer-to-polymer ratio, respectively, as the stirring speed decreased. The results obtained indicate that the effect of
X1 (drug -to-polymer-to-polymer) is more significant than
X2 (stirring speed). This means that, as the stirring speed increases, the particle size decreases, and as a result the percentage of mucoadhesion could be directly affected.
Thus, one can conclude that the amount of polymer (Carbopol-934P) and the stirring speed directly affect the percentage of mucoadhesion, as well as the particles size of microspheres.
Factorial equation for drug entrapment efficiency
The drug entrapment efficiency and t80 are important variables for assessing the drug loading capacity of microspheres and their drug release profile. These parameters are dependent on the process of preparation, physicochemical properties of drug, and formulation variables.
The linear model generated for drug entrapment efficiency was found to be significant, with an F-value of 4.39 (p < 0.0001) and R2 value of 0.9165:
Drug entrapment efficiency = 48.14 + 7.71X1 -3.28X2 -4.57X1X2 -16.71X12 +0.28 X22 (7)
The counter plot (
Figure 5c) shows that the percentage of drug entrapment efficiency of microspheres increased from 25.0 to 29.0 and 33.0 to 45.0, at lower and higher levels of drug-to-polymer-to-polymer ratio, respectively, as the stirring speed decreased. However, at a medium level of drug-to-polymer-to-polymer ratio, as the stirring speed decreased, the percentage of drug entrapment efficiency of microspheres showed an increase from 40.0 to 54.0. The results obtained, indicate that the effect of
X1 (drug-to-polymer-to-polymer) is more significant than
X2 (stirring speed). Moreover, the stirring speed had a negative effect on the percentage of drug entrapment efficiency (i.e. as the stirring speed increased, the particle size decreased and consequently the drug entrapment efficiency also decreased).
Factorial equation for t80
The linear model generated for t80 was found to be significant, with an F-value of 115.91 (p < 0.0001) and R2 value of 0.9997:
t80 = 533.47 – 167.16X1+ 43.88X2 -25.57X1X2 -58.71X12 +5.57 X22 (8)
The counter plot (
Figure 5d) shows that the percentage of drug released
in-vitro from microspheres decreased at the lower and higher levels of drug-to-polymer-to-polymer ratio, respectively, as the stirring speed decreased. The results depicted in
Table 3 indicate that the percentage of drug released
in-vitro is highly dependent on the drug-to-polymer-to-polymer ratio and the stirring speed. The drug-to-polymer-to-polymer ratio has a negative effect on t
80, while stirring speed has a positive effect on t
80. Consequently, as the particle size decreases, the drug release also decreases.
A numerical optimization technique, using the desirability approach, was employed to develop a new formulation with the desired responses. Constraints like maximizing the percentage of mucoadhesion, drug entrapment efficiency, particle size and the amount of drug released after 12 h, in addition to minimizing the t
80, were set as goals to locate the optimum settings of independent variables in the new formulation. The optimized microsphere formulation (J
10) was developed, using a 1:3:1.25 drug-to-polymer-to-polymer ratio and a stirring speed of 950 rpm. The optimized formulation was evaluated for the percentage of mucoadhesion, drug entrapment efficiency, particle size and the amount of drug released. The results of experimentally observed responses and those predicted by mathematical models, along with the percentage prediction errors were compared. The prediction error, for the response parameters ranged between 0.52 and 2.18%, with an absolute error value of 1.26 ± 0.72%. The low values of error indicate the high prognostic ability of factorial equation methodology. The amount of drug released from the optimized formulation was found to be low and it had a t
80 value of 405 min. Thus, batch J
4 was selected for further studies, since it exhibited a high t
80 value of 496 min and seems to be a promising candidate for achieving drug release up to 12 h. The drug release profile of batch J
4 is shown in
Figure 4. This graph revealed that drug release rate slowed down after 2 h.
The results of curve fitting of the best batch into different mathematical models are given in
Table 2.
| Hixon-Crowell | Korsemeyer and Peppas | Weibull |
|---|
| SSR | 95.11 | 158.47 | 57.24 |
| F-value | 11.62 | 22.39 | 8.05 |
| Correlation Coefficient | 0.9871 | 0.9825 | 0.9931 |
| Slope | 0.005 | 0.947 | 1.210 |
| Intercept | –0.99 | –2.36 | –2.12 |
The mechanism of drug release from the microspheres was found to be diffusion controlled, since the plots of the cumulative percentage of drug release versus the square root of time were found to be linear with the regression coefficient (R2) values, ranging from 0.9784 to 0.9879 for the best batch. The release profile fitted the Weibull equation, and an F-value of 8.05 was obtained. The value obtained for the correlation coefficient was found to be 0.9931. The values of slope and intercept were found to be 1.21 and –2.12, respectively. The release profile fitted to the Korsmeyer-Peppas equation, produced an F-value of 22.39. The value of correlation coefficient was found to be 0.9825. The values of slope and intercept were found to be 0.947 and –2.36, respectively. Finally, the release profile fitted to the Hixon-Crowell equation, gave an F-value of 11.62. The value of correlation coefficient was found to be 0.9871. The values of slope and intercept were found to be 0.005 and –0.99, respectively. The results of F-statistics were used for the selection of the most appropriate model. As a result, it was concluded that the release profile fitted best to the Weibull equation (F-value =8.05).
In-vivo studies
A rapid reduction in heart rate was observed with pure propranolol hydrochloride and the heart rate also recovered rapidly to the normal level within 5 h (
Figure 6). In the case of propranolol hydrochloride mucoadhesive microspheres, the reduction in heart rate was slow and reached a maximum reduction of 47 percent within 5 h after oral administration. This reduction in heart rate was sustained over a longer period of time (10 h). The 40 percent reduction in heart rate could be considered as a significant anti-hypertensive effect (
28). In pure drug, the significant anti-hypertensive effect (40 percent) was maintained during the periods from 0.5 to 5 h following oral administration of propranolol hydrochloride. Whereas, in case of mucoadhesive microspheres, the effect was maintained for a period of 0.5 to 10 h. The sustained anti-hypertensive effect observed over a longer period of time in case of mucoadhesive microspheres was due to a slow release rate of drug, as well as the mucoadhesive properties of microspheres.
In conclusion, it could be said that the propranolol hydrochloride mucoadhesive microspheres developed, using a 32 full factorial design, showed a high percentage of mucoadhesion and drug entrapment efficiency. They also exhibited a sustained drug release property for peroral use in the form of capsule. Drug-to-polymer-to-polymer (propranolol hydrochloride-ethyl cellulose-Carbopol-934P) ratio, as well as the stirring speed had a significant influence on the percentage of mucoadhesion, drug entrapment efficiency, particle size and t80. The optimized propranolol hydrochloride mucoadhesive microsphere formulation, developed using the desirability approach, showed a greater anti-hypertensive effect over a period of 10 h, compared to the propranolol hydrochloride powder. This would indicate the potential of mucoadhesive propranolol hydrochloride microspheres for use in the provision of a sustained anti-hypertensive effect.